Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6181-6185

  Frazee, Erin N ^a   Kuper, Philip J ^a   Schramm, Garrett E ^a   Larson, Scott L ^a   Kashani, Kianoush B ^a   Osmon, Douglas R ^a   Leung, Nelson ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; COHORT ANALYSIS; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE;

AGED; ANTI-BACTERIAL AGENTS; BODY WEIGHT; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; FEMALE; HEMOFILTRATION; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84869225055     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00459-12     Document Type: Article

References (33)

1. Ali T, et al. 2007. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J. Am. Soc. Nephrol. 18:1292-1298.
2. Angus DC, et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
3. Bagshaw SM, George C, Bellomo R. 2008. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol. Dial. Transplant. 23:1569-1574.
4. Bellomo R, et al. 2009. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 361:1627-1638.
5. Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A. 1999. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med. 25:1100-1104.
6. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. 2002. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit. Care Med. 30:2205-2211.
7. Boussekey N, et al. 2008. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med. 34:1646-1653.
8. Bressolle F, et al. 1994. Clinical pharmacokinetics during continuous haemofiltration. Clin. Pharmacokinet. 26:457-471.
9. Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P. 2011. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int. J. Antimicrob. Agents 38:152-156.
10. Dellinger RP, et al. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36:296-327.
11. Jeffres MN, et al. 2006. Predictors of mortality for methicillin- resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947-955.
12. Joy MS, Matzke GR, Frye RF, Palevsky PM. 1998. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am. J. Kidney Dis. 31:1019-1027.
13. Kumar A, et al. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is a critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596.
14. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
15. Macias WL, Mueller BA, Scarim SK. 1991. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin. Pharmacol. Ther. 50:688-694.
16. Mueller BA, Pasko DA, Sowinski KM. 2003. Higher renal replacement therapy dose delivery influences on drug therapy. Artif. Organs. 27:808-814.
17. O'Reilly P, Tolwani A. 2005. Renal replacement therapy III: IHD, CRRT, SLED. Crit. Care Clin. 21:367-378.
18. Overberger P, Pesacreta M, Palevsky PM. 2007. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin. J. Am. Soc. Nephrol. 2:623-630.
19. Palevsky PM, et al. 2008. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359:7-20.
20. RENAL Study Investigators. 2008. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit. Care Resusc. 10:225-230.
21. Roberts DM, et al. 2012. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit. Care Med. 40:1523-1528.
22. Ronco C, et al. 2000. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30.
23. Rybak MJ, et al. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327.
24. Shen HN, Lu CL, Yang HH. 2010. Epidemiologic trend of severe sepsis in Taiwan from 1997 through 2006. Chest 138:298-304.
25. Shorr AF, Micek ST, Jackson WL, Jr, Kollef MH. 2007. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit. Care Med. 35:1257-1262.
26. Tolwani AJ, et al. 2008. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J. Am. Soc. Nephrol. 19:1233-1238.
27. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41:1159-1166.
28. Uchino S, et al. 2007. Continuous renal replacement therapy: a world-wide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 33:1563-1570.
29. Uchino S, Cole L, Morimatsu H, Goldsmith D, Bellomo R. 2002. Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med. 28:1664-1667.
30. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. 2003. Continuous is not continuous: the incidence and impact of circuit "downtime" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med. 29:575-578.
31. Uchino S, et al. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818.
32. Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK. 2010. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit. Care Med. 38:1360-1369.
33. Wilson FP, Berns JS. 2012. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin. Nephrol. 77:329-331.